{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Screening 1', 'Treatment Period 2', 'Follow-Up Period\u00b3', 'Follow-Up', 'Contact4', '11/', '16/', 'Study Visit', 'S1/S2/S3', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '12', '13', '14', '15', 'PW15', '6', '17', '18', 'PW2', 'Week (W)/', '-42 to -14', 'Day 17', 'W1', 'W3', 'W4/', 'W6', 'W9', 'W12/', 'W15', 'W18', 'W21', 'W24/', 'W28/', 'W36/', 'W48/', 'W60/', 'W72/', 'W96/', 'W120/', 'Month (M)', 'days', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M15', 'M18', 'M42', 'M66', 'Visit Window ( days)', '(+3)', '(+1)', '(+3)', '(+1)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+3)', '(+7)', '(+7)', '(+7)', '(+7)', '(+7)', '(+7)', '(+14)', '(+14)', 'HbAlc 26', 'X', 'X', 'X', 'X', 'X', 'Urinalysis', 'X', 'X', 'X', 'X', 'X', 'X', 'ADA/NAb samples', '27', 'X', 'X28', 'X', 'X', 'AE, SAE assessment 29', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Concomitant medications', 'X', 'X', 'GO-QoL Questionnaire', 'Biomarker samples 30', 'PK samples', '31', 'X28', 'Contact (phone/email) to assess', 'additional TED treatment', '32', 'X', 'X', 'ADA=anti-drug antibody; AE=adverse event; CAS=Clinical Activity Score; ECG=electrocardiogram; FT3=free triiodothyronine; FT4=free thyroxine; FU=Follow-Up;', \"GO-QoL=Graves' Ophthalmopathy Quality of Life Questionnaire; HbAlc=glycated hemoglobin; M=month; NAb=neutralizing antibody; PK=pharmacokinetic;\", 'PW=premature', 'withdrawal; SAE=serious adverse event; TED=thyroid eye disease; TSH=thyroid stimulating hormone; W=week.', 'Footnotes:', '1. Screening procedures can take place over more than 1 day/clinic visit provided consent is obtained first and all assessments are completed within the designated window.', '2. Double-masked Treatment Period. Subjects who are proptosis non-responders at Week 24 are eligible to enroll in an open-label extension study in which all subjects will', 'receive teprotumumab 20 mg/kg (10 mg/kg for the first infusion and 20 mg/kg for the remaining infusions).', '3. Proptosis responders and non-responders who choose not to enroll in the open-label extension study will participate in a 48-week Follow-Up Period.', '4. Subjects who complete the Week 72 Visit will be contacted viaphone or email by research staff to enquire if any treatment for TED has been received since last study contact.', '5. If a subject prematurely discontinues study drug during the Treatment Period, they will return for a clinic visit and undergo the Week 24 assessments, with the exception of the', 'collection of blood samples for PK and ADA evaluations. Subjects will be encouraged to continue study participation in the Follow-Up Period.', '6. If a subject prematurely discontinues from the study during the Follow-Up Period, they will return for a clinic visit and undergo the Week 72 assessments prior to discharge.', '7. On Day 1 (Baseline), subjects will be randomized and receive the first dose of study drug; however, Baseline assessments will be performed prior to dosing.', \"8. Medical history including tobacco use history and Graves' disease and treatment history.\", '9. TED must be moderate to severe in intensity (non-sight threatening but appreciable impact on daily life) with an onset of symptoms (as determined by subject records) within', '9 months prior to the Baseline Visit for study enrollment.', '10. Dosing will be adjusted if there is a change in weight during the Treatment Period. The weight obtained at Week 12 can be used in dose calculations beginning at Week 12 or', 'Week 15.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 30 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '11. Subjects will be randomized in a 1:1 ratio (stratified by tobacco use status) to receive either: a) teprotumumab (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the', 'remaining 7 infusions) or b) placebo (q3W for all 8 infusions).', '12. Phone (or email) contact by research staff focusing on safety and tolerability aspects will be made the day after infusion for the first and second infusions, and thereafter as', 'deemed appropriate. In addition, subjects who experience an infusion-associated event after any subsequent infusion will also be contacted by phone (or email) by research', 'staff the day after the infusion, and thereafter as deemed appropriate.', '13. CAS must be > 4 for enrollment and randomization.', '14. Subjects whose CAS score decreases 2 or more points in the study eye from Screening are not eligible for randomization.', '15. Subjects who have a 2 mm decrease in proptosis in the study eye from Screening are not eligible for randomization.', '16. Serum pregnancy test at Screening and urine pregnancy tests prior to dose at all other visits, as applicable. Perform for female subjects of childbearing potential (including', 'those with an onset of menopause <2 years prior to Screening, non-therapy-induced amenorrhea for <12 months prior to Screening, or not surgically sterile [absence of ovaries', 'and/or uterus]).', '17. Pregnancy test only performed for female subjects of childbearing potential who enter the Follow-Up Period but discontinue study participation prior to Week 48.', '18. Physical exam will include assessment of presence or absence of pretibial myxedema on Day 1 and Week 24 (or PW) of the Treatment Period and Week 72 (or PW) of the', 'Follow-Up Period. If present, measurements of instep and calf will be taken.', '19. Height will be measured at Screening only.', '20. Ophthalmic exam: best corrected visual acuity, pupil exam, color vision assessment, Ishihara color plates (or equivalent) or related red desaturation, intraocular pressure, and', 'slit lamp exam. If significant abnormalities are noted compared to previous visits, including a loss of 2 lines or more of vision, development of pupil abnormalities including', 'APD, rise in intraocular pressure, development of corneal infiltrates or other abnormalities not here specified but of concern to the ophthalmologist, further investigations of', 'visual function will be conducted according to the ophthalmologist decision.', '21. Subjects who have decreased best-corrected visual acuity due to optic neuropathy (defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or', 'color defect secondary to optic nerve involvement within the last 6 months) are not eligible for randomization.', '22. Vital signs (heart rate, blood pressure, respiratory rate, temperature) will be measured at all clinic visits. Vital signs will be measured pre- and post-infusion on Day 1 and', 'Week 3, and pre-dose on all other infusion days. Additional vital signs will be monitored if infusion-associated AEs occur (see Section 9.5.5.4 for details).', '23. Non-diabetic subjects should be fasting at Weeks 1 and 4 only. Diabetic subjects should be fasting at each visit blood glucose', 'is', 'evaluated.', '24. ALT/AST must be 3 x the upper limit of normal (ULN) and serum creatinine must be <1.5 X the ULN according to age to be eligible for randomization.', '25. Subjects must be euthyroid with the baseline disease under control or have mild hypo- or hyperthyroidism (defined as free thyroxine [FT4] and free triiodothyronine [FT3]', 'levels < 50% above or below the normal limits). Every effort should be made to correct the mild hypo- or hyperthyroidism promptly and to maintain the euthyroid state for the', 'full duration of the clinical trial.', '26. HbAlc must be < 9.0% for randomization. If the HbAlc is elevated and considered clinically significant at any time point after Screening, it will be repeated approximately', 'every 45 days until it returns to normal or baseline value.', '27. If a sample is positive in the ADA test, after confirmatory and reactive titer testing, the sample will then be tested for NAb. If the subject tests positive for NAb, he/she will be', \"followed until levels either revert to Baseline or the subject's value decreases or remains stable. Any subject with a positive NAb test at Week 72 (or PW) during the\", \"Follow-Up Period will continue to be followed until the subject's value decreases or remains stable.\", '28. Not collected for subjects who prematurely discontinue from the Treatment Period.', '29. Adverse events (AEs) that occur within 2 weeks prior to Day 1 and prior to dosing on Day 1 will be considered baseline signs/symptoms. Adverse events occurring or', 'worsening after the dose on Day 1 through the end of the Treatment Period will be considered treatment-emergent AEs (TEAEs). Adverse events occurring', 'or', 'worsening', 'during the Follow-Up Period will be considered postdose AEs. All SAEs that occur from the signing of informed consent through 30 days after study discontinuation will be', 'recorded.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 31 of 117']\n\n###\n\n", "completion": "END"}